Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 22.12.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
22.12.23AFT Pharmaceuticals - R&D pipeline strengthens with new candidate368AFT Pharmaceuticals has bolstered its R&D pipeline with the addition of a new product candidate, HY-090, a locally acting novel molecule, targeting Burning Mouth Syndrome (BMS), a condition with no...
► Artikel lesen
22.12.23Actinogen Medical - Phase IIb XanaMIA study opens first study site325Actinogen Medical has opened the first investigational study site for its Phase IIb XanaMIA trial of lead candidate Xanamem in patients with cognitive impairment (CI) associated with mild-to-moderate...
► Artikel lesen
22.12.23Tinexta - Business Innovation expansion in France445The announcement of the binding and irrevocable offer to gradually acquire the whole of ABF Group (ABF) is consistent with Tinexta's strategy of internationalising its core businesses, in this case...
► Artikel lesen
22.12.23Basilea Pharmaceutica - Refilling the pipeline for growth379Basilea recently expanded its antifungal and antibacterial product pipeline with three new assets, including the latest addition, fosmanogepix. As a broad-spectrum antifungal (including multidrug-resistant...
► Artikel lesen
22.12.23Pierre et Vacances - Local hero482Pierre et Vacances is successfully repositioning itself under new management in the increasingly popular market of local and environmentally friendly tourism. After last year's restructuring, premiumisation...
► Artikel lesen
22.12.23IRLAB Therapeutics - IRL757 Phase I-ready with support from MJFF347IRLAB Therapeutics has announced that IRL757, a drug candidate being developed for the treatment of apathy in Parkinson's disease (PD) and other neurological conditions, is now Phase I-ready. Management...
► Artikel lesen